SPECIAL REPORTS

Progress of echinococcosis control in China, 2021

  • KUI Yan ,
  • XUE Chuizhao ,
  • WANG Xu ,
  • LIU Baixue ,
  • WANG Ying ,
  • WANG Liying ,
  • YANG Shijie ,
  • HAN Shuai ,
  • WU Weiping ,
  • XIAO Ning
Expand
  • National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Shanghai 200025, China

Received date: 2023-01-27

  Revised date: 2023-03-27

  Online published: 2023-04-20

Supported by

National Key Research and Development Program of China(2021YFC2300800);National Key Research and Development Program of China(2021YFC2300804)

Abstract

In order to understand the work progress in nationwide control of echinococcosis, data related to echinococcosis prevention and control in 2021 were collected and analyzed. As of the end of 2021, echinococcosis was found endemic in 370 counties (city, district, banner) covering 30 421 endemic villages in China. There were 47 584 117 permanent residents living in endemic townships. In 2021, 26 773 echinococcosis cases were documented in endemic counties (cities, districts, banners), with an average prevalence 0.06% (26 773/47 584 117), among them, 16 625 cases were of cystic, and 8 327 cases alveolar echinococcosis, 311 cases mixed infection, 1 510 cases unclassified. A total of 1 346 cases were newly diagnosed in 2021, including 1 075 cases of cystic echinococcosis, 86 cases of alveolar echinococcosis, 7 cases of mixed infection, and 178 cases of unclassified. In 2021, population screening by abdominal ultrasound scanning was performed in all endemic provinces (autonomous regions) for 4.471 7 million person/times, of them, 0.871 5 million person/examinations were for people under age of 12, 3.600 2 million person/times for permanent residents aged ≥ 12; serological examination was carried out for 11 358 person/times. Recorded from 370 surveillance sites in 2021, positive rate of ultrasound detection in people under age of 12 was 0.02% (72/336 959), of which 58.33% (42/72) were newly diagnosed. The positive rate of ultrasound imaging in permanent residents aged ≥ 12 was 0.26% (922/355 006) in type Ⅰ, Ⅱ endemic counties (city, district, banner), and the newly diagnosed patients accounted for 10.52% (97/922) of the detected patients. In 2021, 19 552 people received drug treatment, 14 440 people received liver and kidney function tests or treatment of adverse reactions. A total of 1 792 patients received surgical treatment, among them cystic echinococcosis accounted for 71.15% (1 275/1 792) and alveolar echinococcosis accounted for 23.66% (424/1 792). In 2021, the follow-up results showed that 3 063 cases were cured, 22 660 cases responded to the treatment, 2 356 cases failed in the treatment, 359 cases died (the cause of death was not echinococcosis), 285 cases were excluded, 301 cases were lost in follow-up, 312 cases had not completed the follow-up, and 146 cases migrated to other places. In 2021, there were 2 626 679 dogs in endemic townships (towns) nationwide, of which 2 389 828 were registered and documented. In 35 019 villages, deworming was conducted for dogs, with 25 844 226 deworming for domestic dogs and 131 315 deworming drug sites were distributed for wild canines. A total of 555 688 fecal samples from domestic dogs were collected and tested, of which 2 614 were found Echinococcus coproantigen positive, with a positive rate of 0.47% (2 614/555 688). Of wild canidae, 54 266 field fecal samples were collected and tested, among which, 422 were found Echinococcus coproantigent positive, with a positive rate of 0.78%. A total of 222 844 slaughtered livestock were randomly examined, among which 1 408 were positive, with a positive rate of 0.63% (1 408/222 844); and 56 124 field rodents were examined, of which 599 were found positive, with a positive rate of 1.07% (599/56 124). The epidemic state of echinococcosis has been basically controlled, but there are still many difficulties and challenges in the control and prevention. It is noted that there may be flaws in the control of the source of infection in some endemic areas, and it is likely that there might exist transmission chain in wild environment. It is imperative to continuously advance the comprehensive intervention areas as gripper to explore and optimize the control strategy, enhance the capacity of primary disease control institutions for control of echinococcosis, carry out pilot trial for controlling echinococcosis transmission in wild field, strengthen the surveillance-early warning system to further curb the epidemic of echinococcosis.

Cite this article

KUI Yan , XUE Chuizhao , WANG Xu , LIU Baixue , WANG Ying , WANG Liying , YANG Shijie , HAN Shuai , WU Weiping , XIAO Ning . Progress of echinococcosis control in China, 2021[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2023 , 41(2) : 142 -148 . DOI: 10.12140/j.issn.1000-7423.2023.02.003

References

[1] Torgerson PR, Budke CM. Echinococcosis: an international public health challenge[J]. Res Vet Sci, 2003, 74(3): 191-202.
[2] Wang Q, Yang L, Wang YF, et al. Disease burden of echinococcosis in Tibetan communities: a significant public health issue in an underdeveloped region of Western China[J]. Acta Trop, 2020, 203: 105283.
[3] Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: advances in the 21st century[J]. Clin Microbiol Rev, 2019, 32(2): e00075-e00018.
[4] Wu WP, Wang H, Wang Q, et al. A nationwide sampling survey on echinococcosis in China during 2012—2016[J]. Chin J Parasitol Parasit Dis, 2018, 36(1): 1-14. (in Chinese)
  (伍卫平, 王虎, 王谦, 等. 2012—2016年中国棘球蚴病抽样调查分析[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(1): 1-14.)
[5] McManus DP, Zhang WB, Li J, et al. Echinococcosis[J]. Lancet, 2003, 362(9392): 1295-1304.
[6] Craig PS, Giraudoux P, Wang ZH, et al. Echinococcosis transmission on the Tibetan Plateau[J]. Adv Parasitol, 2019, 104: 165-246.
[7] Kui Y, Cao CL, Tian S, et al. Analysis on the current situation of personnel constitution in nine provincial institutions of parasitic disease control and prevention[J]. Chin J Parasitol Parasit Dis, 2017, 35(3): 313-317. (in Chinese)
  (蒉嫣, 曹淳力, 田申, 等. 中国9省(自治区)级寄生虫病预防控制机构人才队伍现状分析[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(3): 313-317.)
[8] Han S, Kui Y, Xue CZ, et al. The endemic status of echinococcosis in China from 2004 to 2020[J]. Chin J Parasitol Parasit Dis, 2022, 40(4): 475-480. (in Chinese)
  (韩帅, 蒉嫣, 薛垂召, 等. 2004—2020年全国棘球蚴病疫情分析[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(4): 475-480.)
[9] Kui Y, Liu BX, Wang X, et al. Epidemiological characteristics of echinococcosis in non-endemic PLADs, China, 2017—2020[J]. China CDC Wkly, 2021, 3(51): 1084-1088.
[10] Barth TFE, Casulli A. Morphological characteristics of alveolar and cystic echinococcosis lesions in human liver and bone[J]. Pathogens, 2021, 10(10): 1326.
[11] Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans[J]. Acta Trop, 2010, 114(1): 1-16.
[12] Wang LY, Wang Q, Cai HX, et al. Evaluation of fecal immunoassays for canine Echinococcus infection in China[J]. PLoS Negl Trop Dis, 2021, 15(3): e0008690.
[13] Xiong YH, Zheng B. The analytical research on patented technology of drugs for echinococcosis prevention and control in China[J]. Chin Health Stand Manag, 2021, 12(9): 5-9. (in Chinese)
  (熊彦红, 郑彬. 中国棘球蚴病防治药物专利技术分析研究[J]. 中国卫生标准管理, 2021, 12(9): 5-9.)
[14] Craig PS, Hegglin D, Lightowlers MW, et al. Echinococcosis: control and prevention[J]. Adv Parasitol, 2017, 96: 55-158.
[15] Rong XM, Fan M, Zhu HP, et al. Dynamic modeling and optimal control of cystic echinococcosis[J]. Infect Dis Poverty, 2021, 10: 38.
[16] Fu MH, Han S, Xue CZ, et al. Contribution to the echinococcosis control programme in China by NIPD-CTDR[J]. Adv Parasitol, 2020, 110: 107-144.
Outlines

/

〈 〉